Cancer Research Journal

Submit a Manuscript

Publishing with us to make your research visible to the widest possible audience.

Propose a Special Issue

Building a community of authors and readers to discuss the latest research and develop new ideas.

Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting

Introduction: Ovarian cancer, the 1st cause of death from gynecological cancer, is any malignant proliferative process developed in the ovary, which may occur after a treated breast cancer. Objectives: To discuss the management and prognosis of ovarian cancer after breast cancer treatment through a series of 3 clinical cases in a Guinean oncology setting. Case 1: A 60-year-old patient presented with an ulcerating tumor of the uterine cervix, after treatment of a CCI, she benefited from 12 courses of palliative chemotherapy and died 04 months after her last course with decompensated anemia. Case 2: the 75-year-old female patient who presented with abdominal distension with ascites associated with a pelvic mass after treatment of a CCI, died of multivisceral failure. Case 3: A 61-year-old hypertensive diabetic patient presented with abdominal distension and a pelvic-abdominal mass. After treatment of a CCI, she underwent an exploratory laparotomy and died at D15 post-op in hypovolaemic shock. Conclusion: This study shows the need to include monitoring of gynecological organs in patients treated for breast cancer. The diagnosis was late and the prognosis was poor.

Ovarian Cancer, Treatment, Breast Cancer, Guinean Oncological Environment

Bah Malick, Toure Alhassane Ismael, Keita Mamady, Cisse Kalil, Souare Mamadou Bobo, et al. (2023). Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting. Cancer Research Journal, 11(3), 105-111.

Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Institut Curie. Breast cancer. [Accessed March 11, 2021]. Available at:
2. Lokossou A. Ovarian cancer: epidemiology, natural history, clinical study. Cours université d'Abomey- Calavi Bénin: 82p. [Accessed 04 February 2021]. Available from
3. Schonfeld SJ, Berrington de Gonzalez A, Visvanathan K, et al. Declining second primary ovarian cancer after first primary breast cancer. J Clin Oncol. 2013; 31 (6): 738-43.a.
4. Zoukar O, Haddad A, Daldoul A et al. Genital metastases from breast cancer: study of 3 cases and literature review. Pan Afr Med J. 2018; 30 (7): 7.
5. Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors. [Accessed 06 February 2021]. Available at:
6. Crouet H, Lesur A, Blanc-Fournier C et al. Ovarian, peritoneal and retroperitoneal metastases in breast cancer. 29th meeting of the French Society of Senology and Breast Pathology (SFSPM). Advanced breast cancer. Avignon, France. 2007. 239p.
7. Wang J., Tian W., Zhou Y. et al. Ovarian metastasis from breast cancer in three Chinese females: Three case reports. China: Wolters Kluwer Health, Inc; 2019; 98 (17); e15395.
8. Dubois N., Willems T., Myant N. Métastase ovarienne du cancer du sein: à propos d'un cas. Rôle de la chirurgie cytoréductrice. Eur J Obst Gyn Reprod Biol; 2009; 38 (3): 242-245.
9. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin. 2009 59 (4): 225-49.
10. Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C et al. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet. 2011; 284 (5): 1283-8.
11. Chabbert-Buffet N, Seroussi B, Chopier J et al. Modalités de fonctionnement d'un centre de prise en charge des femmes à haut risque de cancer du sein et de l'ovaire: l'expérience française de l'hôpital Tenon. Gynecol Obstet Fertil. 2010; 38 (3): 183-92.
12. Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre-and perioperative characteristics. Gynecol Oncol. 2006; 101 (1): 97-101.
13. Le Thai N, Lasry S, Brunet M et al. Cancer de l'ovaire après cancer du sein. 45 cars. J Gynecol Obstet Biol Reprod (Paris). 1991; 20 (8): 1043-8.
14. Gagnon Y, Têtu B. Métastases ovariennes d'un carcinome mammaire. Etude clinicopathologique de 59 cas. Cancer. 1989; 64 (4): 892-8.
15. Le Bouëdec G, de Latour M, Levrel O, Dauplat J. Tumeurs de krükenberg d'origine mammaire. 10 observations. Presse Med. 1997 Mar 29; 26 (10): 454-7.
16. Perrotin F, Marret H, Bouquin R et al. Incidence, diagnostic et pronostic des métastases ovariennes dans le cancer du sein. Gynecol Obstet Fertil. 2001; 29 (4): 308-15.
17. Société canadienne du cancer. Facteurs de risque du cancer du sein. [Consulté le 03 mai 2021]. Disponible sur:
18. Rabban JT, Barnes M, Chen L-M et al. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009; 33 (8): 1125-36.
19. Ayhan A, Guvenal T, Salman MC et al. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol. 2005; 98 (2): 235-41.
20. Abu-Rustum NR, Aghajanian CA, Venkatraman ES et al. Metastatic breast carcinoma to the abdomen and pelvis. Gynecol Oncol. 1997; 66 (1): 41-4.
21. Han X, Jemal A. Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U. S. Am J Prev Med. 2017; 53 (4): 504-7.
22. Schneider J, Lahl J, Kramer W. Risque de cancer du sein à long terme après stimulation ovarienne chez les jeunes donneuses d'ovules: un appel au suivi, à la recherche et au consentement éclairé. Reprod Biomed Online. 2017; 34 (5): 480-5.